Cerecor Rebrands to Avalo Therapeutics

Published on :

Cerecor Rebrands to Avalo Therapeutics. Eighteen months after completing its merger with Aevi Genomic Medicine, Cerecor is rebranding to Avalo Therapeutics. The rebranding to Avalo reflects the company’s aims to focus on three core indications, on immunology, immuno-oncology, and rare genetic diseases.

New Immuno-Oncology Startup out of Baltimore Launches at JPM Healthcare Conference with Veteran Board, Advisors and Officers

Published on :

New Immuno-Oncology Startup out of Baltimore Launches at JPM Healthcare Conference with Veteran Board, Advisors and Officers VerImmune’s Novel technology platform enables redirection of pre-existing natural immunity towards fighting cancer [….]

Q&A with Jaime Rodriguez-Canales, M.D., FEBP – The importance of Multiplex Immunofluorescence in the field of Immune-Oncology

Published on :

Q&A with Jaime Rodriguez-Canales, M.D., FEBP Dr. Rodriguez-Canales is a Senior Pathologist at MedImmune, and Course Director for the recent Multiplex Immunofluorescence in Immune-Oncology Symposium, a Bio-Trac program cosponsored by [….]

Q&A with Immunomic’s Teri Heiland, PhD: What the ‘UNITE’ Technology Platform Could Mean for the Future of Immunotherapy

Published on :

Q&A with Immunomic’s Teri Heiland, PhD What the ‘UNITE’ Technology Platform Could Mean for the Future of Immunotherapy September 25, 2018   Teri Heiland, Ph.D. is the Senior Vice President [….]